Biotron Limited (BITRF)
OTCMKTS
· Delayed Price · Currency is USD
0.0027
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT
Biotron Company Description
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections.
Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited
| Country | Australia |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Michelle Miller |
Contact Details
Address: 66 Hunter Street Sydney, 2000 Australia | |
| Phone | 61 2 9805 0488 |
| Website | biotron.com.au |
Stock Details
| Ticker Symbol | BITRF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000BIT4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD and Executive Director |
| Peter James Nightingale B.Econ, CA | Company Secretary |